南京医药
(600713)
| 流通市值：64.88亿 | | | 总市值：65.80亿 |
| 流通股本：12.90亿 | | | 总股本：13.08亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 27,822,576,569.95 | 13,843,779,763.6 | 54,963,277,449.95 | 41,135,141,888.47 |
| 营业收入 | 27,822,576,569.95 | 13,843,779,763.6 | 54,963,277,449.95 | 41,135,141,888.47 |
| 二、营业总成本 | 27,234,806,874.98 | 13,504,978,803.17 | 53,921,722,737.41 | 40,346,990,541.21 |
| 营业成本 | 26,145,385,652.22 | 12,974,407,093.46 | 51,580,940,619.15 | 38,688,027,990.7 |
| 税金及附加 | 49,267,514.32 | 24,611,029.72 | 118,997,032.71 | 87,052,073.91 |
| 销售费用 | 571,359,933.76 | 286,479,151.72 | 1,199,699,696.55 | 853,806,411.04 |
| 管理费用 | 231,526,826.98 | 105,351,276.04 | 513,476,954.57 | 346,466,905.9 |
| 研发费用 | 16,553,690.48 | 7,611,588.1 | 46,789,558.57 | 25,902,194.31 |
| 财务费用 | 220,713,257.22 | 106,518,664.13 | 461,818,875.86 | 345,734,965.35 |
| 其中:利息费用 | 139,864,841.66 | 64,813,863.01 | 309,014,785.81 | 220,359,117.43 |
| 其中:利息收入 | 5,903,983.13 | 3,467,849.92 | 20,635,964.17 | 12,824,850.5 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 410,597.27 | 199,024.66 | 282,526.03 | 897,521.76 |
| 加:投资收益 | 3,530,736.72 | -1,433,268.66 | 4,793,861.74 | 1,144,013.41 |
| 资产处置收益 | 2,970,207.79 | 1,185,480.36 | 293,733,418.4 | 8,760,583.49 |
| 资产减值损失(新) | -4,212,882.79 | -2,385,726.25 | -25,113,091.63 | -5,365,609.36 |
| 信用减值损失(新) | -79,002,585.25 | -60,713,770.45 | -185,371,662.12 | -122,156,370.71 |
| 其他收益 | 15,045,552.83 | 9,028,992.95 | 30,226,515.95 | 19,978,906.85 |
| 四、营业利润 | 526,511,321.54 | 284,681,693.04 | 1,160,106,280.91 | 691,410,392.7 |
| 加:营业外收入 | 10,566,870.31 | 2,234,660.12 | 39,758,236.98 | 38,675,866.56 |
| 减:营业外支出 | 13,736,433.61 | 4,998,795.26 | 42,236,584.17 | 21,540,606.17 |
| 五、利润总额 | 523,341,758.24 | 281,917,557.9 | 1,157,627,933.72 | 708,545,653.09 |
| 减:所得税费用 | 144,840,734.05 | 70,220,113.31 | 324,959,057.2 | 178,789,080 |
| 六、净利润 | 378,501,024.19 | 211,697,444.59 | 832,668,876.52 | 529,756,573.09 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 378,501,024.19 | 211,697,444.59 | 832,668,876.52 | 529,756,573.09 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 294,471,241.89 | 174,569,585.5 | 624,834,794.91 | 401,971,224.79 |
| 少数股东损益 | 84,029,782.3 | 37,127,859.09 | 207,834,081.61 | 127,785,348.3 |
| 扣除非经常损益后的净利润 | 282,916,751.36 | 168,888,007.4 | 421,334,367.89 | 371,153,677.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.23 | 0.14 | 0.48 | 0.31 |
| (二)稀释每股收益 | 0.2 | 0.12 | 0.43 | 0.28 |
| 八、其他综合收益 | -19,006,250.54 | -13,095,362.19 | -10,643,046.56 | -2,406,240.26 |
| 归属于母公司股东的其他综合收益 | -19,897,340.35 | -13,236,476.9 | -10,478,551.81 | -2,018,916.5 |
| 九、综合收益总额 | 359,494,773.65 | 198,602,082.4 | 822,025,829.96 | 527,350,332.83 |
| 归属于母公司股东的综合收益总额 | 274,573,901.54 | 161,333,108.6 | 614,356,243.1 | 399,952,308.29 |
| 归属于少数股东的综合收益总额 | 84,920,872.11 | 37,268,973.8 | 207,669,586.86 | 127,398,024.54 |
| 公告日期 | 2026-08-29 | 2026-04-30 | 2026-04-11 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |